China continues to sell U.S. Treasury bonds amid Sino-U.S. trade truce uncertainty.

Chanel Holden

2019-08-05 13:30:00 Mon ET

China continues to sell U.S. Treasury bonds amid Sino-U.S. trade truce uncertainty. In mid-2019, China reduces its U.S. Treasury bond positions by $20.5 billion to $1.12 trillion. These Treasury bond positions reach their lowest level or 5% of U.S. government debt in 2017-2019 amid Sino-American trade conflict and economic policy uncertainty. The Chinese Xi administration may use its current status as the top Treasury debtholder as special leverage in the next round of trade negotiations. In response, the Chinese renminbi hovers in the broad range of 6.69x-6.97x per U.S. dollar during the recent time frame. Some investment bankers speculate that as the largest foreign owner of U.S. government bonds, China may implement the nuclear option by offloading lots of Treasury bonds to trigger interest rate hikes in America. These interest rate hikes may inadvertently cause collateral damage to the U.S. economy.

However, Lowy Institute senior fellow Richard McGregor offers the fresh economic insight that China cannot easily manipulate its current U.S. Treasury bond portfolio with no negative impact on the Chinese currency and current account deficit. U.S. trade envoy Robert Lighthizer and Treasury Secretary Steven Mnuchin expect to meet the Chinese hardliners for bilateral trade discussions in Shanghai from late-July to mid-August 2019.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The Trump fiscal trifecta of lower income taxation, new infrastructure, and deregulation has yet to run its natural course.

Becky Berkman

2017-04-25 06:35:00 Tuesday ET

The Trump fiscal trifecta of lower income taxation, new infrastructure, and deregulation has yet to run its natural course.

This nice and clear infographic visualization helps us better decipher the main memes and themes of President Donald Trump's first 100 days in office.

+See More

The new antitrust enforcement paradigm

Joseph Corr

2023-10-14 10:32:00 Saturday ET

The new antitrust enforcement paradigm

Jonathan Baker frames the current debate over antitrust merger review and enforcement in America. Jonathan Baker (2019)   The antitrust paradi

+See More

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

Dan Rochefort

2019-02-03 13:39:00 Sunday ET

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

It can be practical for the U.S. to impose the 2% wealth tax on the rich. Democratic Senator Elizabeth Warren proposes a 2% wealth tax on the richest Americ

+See More

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Rose Prince

2018-02-27 09:35:00 Tuesday ET

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Fed's new chairman Jerome Powell testifies before Congress for the first time. He vows to prevent price instability for U.S. consumers, firms, and finan

+See More

Peter Isard analyzes the proper economic policy reforms and root causes of global financial crises of the 1990s and 2008-2009.

Jonah Whanau

2023-08-14 09:25:00 Monday ET

Peter Isard analyzes the proper economic policy reforms and root causes of global financial crises of the 1990s and 2008-2009.

Peter Isard analyzes the proper economic policy reforms and root causes of global financial crises of the 1990s and 2008-2009. Peter Isard (2005) &nbs

+See More

The world seeks to reduce medicine prices and other health care costs to better regulate big pharma.

Daisy Harvey

2019-06-07 04:02:05 Friday ET

The world seeks to reduce medicine prices and other health care costs to better regulate big pharma.

The world seeks to reduce medicine prices and other health care costs to better regulate big pharma. Nowadays the Trump administration requires pharmaceutic

+See More